Results 301 to 310 of about 355,709 (346)

Diagnostic and prognostic roles of circulating EVs circ_PPAPDC1A in ICIs resistance in NSCLC. [PDF]

NPJ Precis Oncol
Zou FW, Tang YF, Zhang LY, Xu S, Yang SZ, Li WY, Liu ZH.   +6 more
europepmc   +1 more source

Clinical study of aumolertinib versus osimertinib in the treatment of EGFR-mutated advanced non-small cell lung cancer. [PDF]

Discov Oncol
Yang SX, Zhu JD, Ma L, Pan Y, Li QR, Tu WL, Zhang ZQ.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.

New England Journal of Medicine, 2023
BACKGROUND Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutations.
D. Planchard, P. Jänne, Ying Cheng, J. Yang, N. Yanagitani, Sang-we Kim, S. Sugawara, Yan Yu, Yun Fan, S. Geater, K. Laktionov, Chee Khoon Lee, Natalia Valdiviezo, Samreen Ahmed, Jean-Marc Maurel, I. Andrasina, J. Goldman, D. Ghiorghiu, Y. Rukazenkov, Alex Todd, K. Kobayashi   +20 more
semanticscholar   +1 more source

Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.

New England Journal of Medicine, 2023
BACKGROUND Among patients with resected, epidermal growth factor receptor (EGFR)-mutated, stage IB to IIIA non-small-cell lung cancer (NSCLC), adjuvant osimertinib therapy, with or without previous adjuvant chemotherapy, resulted in significantly longer ...
M. Tsuboi, R. Herbst, T. John, T. Kato, M. Majem, C. Grohé, Jie Wang, J. Goldman, Shun Lu, W. Su, F. de Marinis, F. Shepherd, K. Lee, N. Le, A. Dechaphunkul, D. Kowalski, L. Poole, Ana Bolanos, Y. Rukazenkov, Yi‐Long Wu   +19 more
semanticscholar   +1 more source

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.

New England Journal of Medicine, 2023
BACKGROUND Amivantamab has been approved for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertions who have had disease progression during or after platinum-based ...
Caicun Zhou, Ke-jing Tang, B. Cho, Baogang Liu, L. Paz-Ares, Susanna Y. Cheng, Satoru Kitazono, M. Thiagarajan, J. Goldman, J. Sabari, R. Sanborn, Aaron S. Mansfield, Jen-Yu Hung, Michael Boyer, Sanjay Popat, J. Mourão Dias, E. Felip, M. Majem, Mahmut Gumus, Sang-we Kim, A. Ono, John Xie, A. Bhattacharya, Trishala Agrawal, S. M. Shreeve, R. Knoblauch, Keunchil Park, Nicolas Girard   +27 more
semanticscholar   +1 more source

NSCLC

Onkologische Welt, 2023
Nach Daten der Studie FLAURA2 zeigt Osimertinib plus Chemotherapie in der Behandlung des nicht-kleinzelligen Lungenkarzinoms (NSCLC) einen statistisch signifikanten Vorteil beim progressionsfreien Überleben (PFS) im Vergleich zu Osimertinib allein ...

semanticscholar   +1 more source

Applications of genomics in NSCLC

Lung Cancer, 2005
Cisplatin-based chemotherapy has long been the cornerstone of non-small cell lung cancer (NSCLC) management. However, median survival rarely exceeds 1 year. The identification of molecular markers can help to predict response, leading to a broad implementation of the new concept of customized chemotherapy.
ROSELL R, COBO M, ISLA D, SANCHEZ JM, TARON M, ALTAVILLA, Giuseppe, SANTARPIA, Mariacarmela, MORAN T, CATOT S, ETXANIZ O.   +9 more
openaire   +5 more sources

A review of Osimertinib in NSCLC and pharmacist role in NSCLC patient care

Journal of Oncology Pharmacy Practice, 2020
Lung cancer is a complex, genetically heterogeneous disease. It is the most common cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) represents the majority of the diagnosed lung cancer cases. Osimertinib is a new treatment option that demonstrated a superior efficacy over standard epidermal growth factor receptor tyrosine ...
Osama M Al-Quteimat, Amer M Amer
openaire   +3 more sources

Mutations in NSCLC.

Journal of Clinical Oncology, 2014
e18516 Background: Lung cancer has a poor prognosis, with 15-20% five-years survival rate. However, lung cancer treatment has in the last years taken advantage of newly developed targeted therapies...
Eivind Hovig, Odd Terje Brustugun, Daniel Vodak, Jinchang Sun, Susanne Lorenz, Leonardo A. Meza-Zepeda, Åslaug Helland, Ola Myklebost, Sigve Nakken, Ann Rita Halvorsen   +9 more
openaire   +2 more sources

Prognosis in N2 NSCLC

Lung Cancer, 2004
The prognosis of bronchogenic carcinoma in stage III N2 is poor. Five-year survival ranges between 0 and 5%. Lymph-node involvement itself still is the main prognostic factor. Complete lymphadenectomy improves long-term survival in contrast to lymph-node sampling.
Thomas Kyriss, Godehard Friedel, Heikki Toomes, Jutta Zoller, Volker Steger   +4 more
openaire   +2 more sources